Your doctor mentions a new medication. The headlines say it "cuts heart attack risk by 50%." The pharmaceutical brochure shows smiling patients and impressive percentages. But what do these numbers actually mean for you—a specific person with a specific body, history, and set of circumstances?

Clinical trials generate some of the most consequential data in modern life. Their results shape treatment decisions affecting millions, yet the statistical language used to communicate findings often obscures more than it reveals. A 50% reduction sounds dramatic, but reduction from what to what? Measured how? In whom?

Reading a clinical trial as a patient doesn't require a statistics degree. It requires three core skills: knowing what was actually measured, knowing how to translate effect sizes into personal meaning, and knowing whether the study population resembles you. Master these, and you transform from a passive recipient of medical statistics into an active interpreter of evidence about your own health.

Every clinical trial measures something to determine if a treatment works. That something is called an endpoint, and the choice of endpoint shapes everything that follows. The critical distinction is between clinical outcomes—events patients directly experience, like heart attacks, strokes, or death—and surrogate endpoints—measurable biological markers presumed to predict those outcomes, like blood pressure, cholesterol levels, or tumor size.

Surrogates are seductive because they're faster and cheaper to measure. Waiting years to see if patients die produces slow trials. Measuring whether a drug lowers LDL cholesterol takes weeks. But the assumption that moving a marker translates to moving the outcome has failed spectacularly in medical history. Drugs that lowered abnormal heart rhythms after heart attacks increased deaths. Hormone therapy improved cardiac risk markers while raising actual cardiac events.

When you read trial results, ask first: what did they actually measure? A cancer drug that shrinks tumors hasn't necessarily extended life. A diabetes drug that lowers HbA1c hasn't necessarily prevented kidney failure. Surrogate endpoints are hypotheses about what matters; clinical outcomes are what actually matters to your lived experience.

This isn't to dismiss surrogate endpoints—they're often necessary and sometimes well-validated. But the strength of evidence differs substantially. A trial showing reduced mortality carries different weight than one showing improved laboratory values, even when the percentage changes look identical on a pharmaceutical pamphlet.

Takeaway

A treatment that moves a number on a lab report isn't the same as a treatment that changes your life. Always ask what was measured before asking how much it changed.

Suppose a trial reports a drug reduces heart attacks by 50%. Impressive? It depends entirely on what 50% of what. The same data can be presented as three different numbers, each telling a different story.

Relative risk reduction (RRR) compares risk between groups proportionally. If 2% of placebo patients have heart attacks versus 1% of treated patients, that's a 50% relative reduction. Absolute risk reduction (ARR) measures the actual difference: 2% minus 1% equals a 1 percentage-point reduction. Number needed to treat (NNT) inverts the absolute reduction: you must treat 100 patients to prevent one heart attack (1 divided by 0.01).

All three numbers describe identical data, but they create radically different impressions. "Cuts risk in half" feels transformative. "Prevents one event per hundred treated" feels modest. Both are true. Marketing and headlines favor relative risk because the numbers are larger and more dramatic. Treatment decisions require absolute risk because that's what tells you the magnitude of likely personal benefit.

The math is simple: ARR equals the event rate in the control group minus the event rate in the treatment group. NNT equals 1 divided by ARR. When a study reports only relative figures, find the baseline rates and calculate yourself. A 50% reduction from 0.2% to 0.1% means 1,000 people must take the drug for one to benefit—important context when weighing side effects, costs, and inconvenience.

Takeaway

Relative risk tells you how much a treatment shifts the odds. Absolute risk tells you whether those odds were worth worrying about in the first place.

Even a beautifully designed trial with meaningful endpoints and substantial effects may say little about your situation. Statistical results describe populations; you are an individual. The bridge between the two is applicability—whether the trial participants resemble you closely enough that conclusions transfer.

Start with inclusion and exclusion criteria, usually buried in the methods section. Trials commonly exclude patients with multiple conditions, those over a certain age, pregnant women, and people taking other medications. A drug tested only on adults aged 40-65 with no other diagnoses may behave differently in a 78-year-old with kidney disease and three other prescriptions.

Examine the baseline characteristics table, present in nearly every published trial. What was the average age? The sex distribution? The racial and ethnic composition? The severity of disease at enrollment? If the typical participant was a 55-year-old man with mild disease, conclusions about a 75-year-old woman with severe disease require cautious extrapolation, not direct application.

Consider also the treatment setting. Trial participants receive close monitoring, free medication, and frequent follow-up—conditions rarely matching routine care. A treatment effective under ideal conditions (efficacy) may perform differently in everyday practice (effectiveness). Asking "would I have qualified for this trial?" and "do my circumstances resemble those of typical participants?" determines whether the impressive numbers actually predict anything about your outcomes.

Takeaway

Population-level evidence is a starting point, not a verdict. The question isn't whether a treatment works, but whether it works for people enough like you to make the evidence relevant.

Clinical trial interpretation isn't about distrust—it's about precision. The same evidence that supports confident treatment decisions for some patients warrants caution for others, and the difference lies in details that headlines routinely omit.

Three questions cut through most confusion: What was measured—a real outcome or a surrogate? How large is the effect in absolute terms—not just relative percentages? Do the trial participants resemble me closely enough that their results predict mine?

These questions don't replace medical expertise; they enable better conversations with those who have it. Statistical literacy is a form of agency, allowing you to participate meaningfully in decisions about your own body and life.